Search hospitals > Missouri > Saint Louis
Siteman Cancer Center at Christian Hospital
Claim this profileSaint Louis, Missouri 63110
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Lymphoma
Conducts research for Tumors
491 reported clinical trials
69 medical researchers
Summary
Siteman Cancer Center at Christian Hospital is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Lymphoma, Tumors and other specialties. Siteman Cancer Center at Christian Hospital is involved with conducting 491 clinical trials across 572 conditions. There are 69 research doctors associated with this hospital, such as Robert J. Hayashi, Brian A Van Tine, M.D., Ph.D., Douglas R. Adkins, and John F Dipersio, M.D., Ph.D..Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Robert J. HayashiWashington University School of Medicine7 years of reported clinical research
Expert in Tumors
Expert in Lymphoma
58 reported clinical trials
110 drugs studied
Brian A Van Tine, M.D., Ph.D.Washington University School of Medicine2 years of reported clinical research
Expert in Sarcoma
Expert in Soft Tissue Sarcoma
46 reported clinical trials
63 drugs studied
Douglas R. AdkinsWashington University School of Medicine5 years of reported clinical research
Expert in Squamous Cell Carcinoma
Expert in Cancer
33 reported clinical trials
57 drugs studied
John F Dipersio, M.D., Ph.D.Washington University School of Medicine1 year of reported clinical research
Expert in Acute Myeloid Leukemia
Studies Leukemia
33 reported clinical trials
52 drugs studied
Clinical Trials running at Siteman Cancer Center at Christian Hospital
Prostate Cancer
Breast Cancer
Esophageal Adenocarcinoma
Non-Small Cell Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Lung Cancer
Esophageal Carcinoma
Cancer
Colorectal Cancer
Squamous Cell Carcinoma
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Shorter vs Usual Radiation Therapy
for Prostate Cancer
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Recruiting2 awards Phase 310 criteria
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Siteman Cancer Center at Christian Hospital?
Siteman Cancer Center at Christian Hospital is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Lymphoma, Tumors and other specialties. Siteman Cancer Center at Christian Hospital is involved with conducting 491 clinical trials across 572 conditions. There are 69 research doctors associated with this hospital, such as Robert J. Hayashi, Brian A Van Tine, M.D., Ph.D., Douglas R. Adkins, and John F Dipersio, M.D., Ph.D..
Where is Siteman Cancer Center at Christian Hospital located?
The Siteman Cancer Center at Christian Hospital is situated at 11133 Dunn Rd, St. Louis, MO 63136. This center is a key part of the Siteman Cancer Center network, which also encompasses facilities at the Washington University Medical Campus, West County, North County, and Barnes-Jewish Hospital.
Who should I call to ask about financial aid or insurance network?
**Siteman Cancer Center at Christian Hospital - Financial and Insurance Information**
- For financial assistance, contact the Social Work Services and Financial Assistance department via the main Siteman Cancer Center contact information. They assist with insurance understanding and financial management of care.
- Insurance inquiries can be directed to the Patient & Family Services section on the Siteman Cancer Center website, providing insights on insurance and patient care approach.
- Visit the Payment Information page on the Siteman Cancer Center website for details on billing and financial assistance policies.
- For billing and financial assistance questions, contact BJC HealthCare at (314) 747-8845 or toll-free (844) 747-8845. They offer support for financial assistance programs for uninsured or underinsured patients.
What insurance does Siteman Cancer Center at Christian Hospital accept?
The Siteman Cancer Center at Christian Hospital accepts various commercial healthcare plans, including Cigna, First Health/Coventry Health Care National Network, Humana, MultiPlan, and Private Health Care Systems (PHCS). Christian Hospital and Northwest HealthCare, members of BJC HealthCare, offer world-class medical care to North County, Greater St. Louis County, and Southern Illinois. For details on insurance plans accepted and the Blood and Marrow Transplant Program, visit the Siteman Cancer Center website.
What awards or recognition has Siteman Cancer Center at Christian Hospital received?
Siteman Cancer Center at Christian Hospital, situated in Saint Louis, Missouri, ranks as a premier U.S. cancer institution, holding the No. 10 spot among U.S. cancer centers. It is renowned for its extensive research programs and provides world-class care across a broad spectrum of cancer diagnoses. Specialized teams deliver innovative treatments at various locations, including the Siteman Cancer Center at Northwest HealthCare.